Targeted Proteomics of Lung Squamous Cell Carcinomas

To address the complexity of cancer, liquid chromatography-multiple reaction monitoring mass spectrometry (LC-MRM) panels provide the capability to quantify clinical biomarkers and emerging protein markers to establish the context of tumor phenotypes that provide highly relevant supporting information. The resulting targeted proteomics data will empower translational researchers to move protein biomarker panels through the process from discovery to clinical use. Here, targeted proteomics panel measurements provide pathway-level evaluations of key biological drivers (e.g., EGFR signaling), phenotypes (e.g., EMT) and the ability to quantify specific drug targets within the context of a sample cohort of lung squamous cell carcinomas.